Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Sequential Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of CAL-101 in Patients With Select, Relapsed or Refractory Hematologic Malignancies

NCT00710528 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT00710528
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00710528 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Sequential Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of CAL-101 in Patients With Select, Relapsed or Refractory Hematologic Malignancies
Lead sponsor
Gilead Sciences
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2008
Completion date
August 31, 2012
Enrollment
192 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia (aml), chronic lymphocytic leukemia (cll), lymphoma, non-hodgkin (nhl), multiple myeloma (mm)